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Current diagnosis of chronic Chagas disease relies on
serologic detection of specific immunoglobulin G against
Trypanosoma cruzi. However, the presence of parasites
detected by polymerase chain reaction (PCR) in patients
without positive conventional serologic testing has been
observed. We determined the prevalence and clinical char-
acteristics of persons with seronegative results and T. cruzi
DNA detected by PCR in a population at high risk for
chronic American trypanosomiasis. We studied a total of
194 persons from two different populations: 110 patients
were recruited from an urban cardiology clinic, and 84 per-
sons were citizens from a highly disease-endemic area.
Eighty (41%) of persons had negative serologic findings; 12
(15%) had a positive PCR. Three patients with negative
serologic findings and positive PCR results had clinical
signs and symptoms that suggested Chagas cardiomyopa-
thy. This finding challenges the current recommendations
for Chagas disease diagnosis, therapy, and blood transfu-
sion policies.
A
merican trypanosomiasis or Chagas disease is usually
asymptomatic; for this reason, its diagnosis is mainly
based on laboratory tests. During the indeterminate and
chronic clinical periods, detection of immunoglobulin (Ig)
G against Trypanosoma cruzi by more than two different
serologic tests is the standard for diagnosis (1). Moreover,
serodiagnosis is used for epidemiologic surveillance, to
evaluate efficacy of therapy, and for routine testing in
blood banks.
Conversely, direct identification of T. cruzi is the main
tool for diagnosis during the acute phase of Chagas dis-
ease. During the other phases of the disease, detection of
the parasites is rare because of low levels of parasitemia.
However, the development of polymerase chain reaction
(PCR) has allowed detection of T. cruzi in a higher number
of patients with chronic disease. In this stage, the preva-
lence of circulating parasites varies from 21% to 100% by
using PCR, and this variability may be associated with
episodes of reinfection (2–4). Previous reports have
focused on the high sensitivity of PCR test when compared
to serologic findings, xenodiagnosis, or blood culture.
Nonetheless, in some of these investigations a discordant
finding has been observed; parasitemias have been detect-
ed by PCR from serum samples of seronegative persons
(5–9). Although the parasite has been directly observed in
blood of seronegative patients (5), this problem has been
largely ignored in the clinical setting. Parasitemias in
patients with negative serologic findings could represent a
sanitary problem since most diagnostic and therapeutic
recommendations rely on a serologic test. 
We conducted a cross-sectional study in two popula-
tions at high risk for Chagas disease to evaluate the preva-
lence of positive T. cruzi PCR results in seronegative per-
sons. We describe the results of that study as well as the
clinical characteristics of a subgroup of patients.
Patients and Methods
Population and Protocol Study
We studied 194 persons from two populations. We
included an urban population of 110 consecutive patients
who attended the Cardiology Clinic of the Hospital
Privado de Córdoba, Argentina, with epidemiologic or
clinical suspicion of Chagas disease. All the patients were
permanent residents of the city of Córdoba during the last
10 years. Córdoba is considered a low Chagas-endemic
area. The other group consisted of 84 persons from La
Posta, a small rural village of 384 persons located in a
northern rural area of the province of Córdoba. This area is
highly endemic for Chagas disease. All residents of this
area >14 years of age were invited to participate in the
study through informative workshops conducted by spe-
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designed according to Helsinki’s Declaration, and
informed consent was obtained for all patients.
All patients completed an epidemiologic and clinical
questionnaire and had a physical examination. Also, both
urban and rural participants had a 12-lead electrocardio-
gram and a transthoracic echocardiogram.
Serologic Tests
Three serologic assays for all case-patients were per-
formed to detect chronic T. cruzi infection: indirect
immunofluorescence assay (IFA, positive >1:32 dilution;
Biocientífica, Buenos Aires, Argentina), hemagglutination
inhibition assay (positive >1:28 dilution, Biochagas,
Biocientífica, Buenos Aires, Argentina), and enzyme-
linked immunosorbent assay (ELISA, Abbott Labs, Abbott
Park, Illinois). Chronic Chagas disease was defined as the
presence of >2 positive serologic determinations (1). Also,
anti-cruzipain antibodies were detected by ELISA as pre-
viously described (10,11).
PCR for Identification of Trypanosoma cruzi
Peripheral blood samples were drawn from each study
participant for PCR detection of T. cruzi, as previously
described (12,13). Four milliliters of blood was transferred
to guanidine-EDTAcontaining tubes until DNAextraction.
We collected 600 mL of blood to separate DNA by using
conventional technique of fenol: chloroform: isoamyl
alcohol and then ethanol precipitation. Finally, the solution
was suspended in free-endonuclease sterile water. DNA
amplification was carried out in 50 mL of a mixture con-
taining 10 mM 10 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM
MgCl2, 0.2 mM of each deoxinucleoside triphosphate,
1.25 U Taq polymerase (Perkin Elmer Cetus Corp,
Norwalk, CT), and 1 mM of each primer. We amplified a
sequence of 220 bp, which corresponds to a family of E13
genes with high repetition in the genome of T. cruzi; the
sequence of the primers used was: O1, 5′-TGGCTTG-
GAGGAGTTATTGT-3′; O2, 5′-AGGAGTGACGGTTG-
ATCAGT-3′ (12). The reaction was initiated with 10 min
of denaturalization at 94°C and 30 cycles of amplification,
each consisting of 1 min at 94°C, 1 min at 55°C, and 2 min
at 63°C in a Perkin-Elmer-Cetus terminal cycler. We ana-
lyzed the PCR product in a 1.6% agarose gel. In all sam-
ples, DNA from cultivated T. cruzi epimastigotes of
Tulahuen strain was used as positive control. Negative
control consisted of a specimen without DNA. Also, 330-
bp fragment of the β-actin gene (Promega, Madison, WI)
was amplified with the same procedure as E13 fragment to
check DNA quality and to show amplification inhibitors.
Statistical Analysis
Data are presented as mean ±SD or as number and per-
centage of cases. We used chi-square test to compare cate-
gorical variables between groups. A value of p < 0.05 was
considered significant.
Results
Characteristics of both urban and rural populations are
shown in Table 1. Results of serologic testing for 76 (69%)
and 38 (44%) persons from urban and rural populations,
respectively, were positive for T. cruzi infection. Globally,
80 (41%) persons did not fulfill criteria of serologic diag-
nosis of Chagas disease (in all cases, IFA test was nega-
tive). In eight of nine rural seronegative patients, anti-
cruzipain antibodies were investigated with negative
results. 
T. cruzi was detected by PCR amplification of a
nuclear DNA fragment by using the O1/O2 primers (see
Materials and Methods). This reaction has been previous-
ly demonstrated to be highly specific to detect T. cruzi in
blood samples (12). Parasitemia by PCR assay was detect-
ed in 34 (17%) of 194 persons and was more frequently
found in rural than in urban populations (20 and 14 posi-
tive persons, respectively; p = 0.05) (Figure). When only
the seronegative population was considered, PCR was
positive in 12 (15%) persons (3 and 9 from urban and
rural population, respectively; p = 0.36). Clinical charac-
teristics of these patients are shown in Table 2. Only one
patient (from the urban group) had a previous positive
Machado Guerreiro test. Two of three urban patients were
born in a highly disease-endemic area. Disease in all of
these urban patients was controlled a year after recruit-
ment, and subsequent serologic testing was negative. Of
the rural case-patients (born and living in La Posta), none
reported previous positive serologic findings.
Electrocardiogram and echocardiogram were performed
for four patients from a rural area (Table 2).
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Table 1. Demographic and laboratory characteristics of study participants
a 
Variable  Total (n = 194)  Urban population (n = 110)  Rural population (n = 84) 
Age, mean ± SD (y)  52 ±14  56 ±14  48 ±15 
Male (%)  36  37  33 
Negative serologic finding, n (%)  80 (41)  34 (31)  46 (54) 
Positive PCR assay, n (%)  34 (17)  14 (13)  20 (24) 
Positive PCR assay and negative serologic findings, n (%)  12 (6)  3 (9)  9 (20) 
aPCR, polymerase chain reaction. Discussion
When T. cruzi infects a mammal, several immunologic
reactions occur that eliminate the parasite. First, a cellular
immune response attempts to isolate the microorganism
and avoid its wide spread. Simultaneously, a humoral
response occurs, with IgM antibodies first and IgG anti-
bodies 2–3 weeks later. However, because of the lack of
efficacy of these mechanisms, the parasite persists in low-
density tissues and in turn, triggers an inflammatory
response, resulting in tissue damage during the chronic
period of the disease (14). Parasites are rarely isolated
from blood or tissue from chronically infected patients,
and the diagnosis is based on serologic analysis.
In our study, we observed that persons with positive T.
cruzi in blood and negative serologic findings could be
detected in a population with high epidemiologic risk. This
observation has been previously reported in Wincker et al.
(5), who studied PCR technique using serum samples from
45 Bolivian children. They found two positive PCR results
in 17 seronegative children, and in one of them, parasites
were seen on direct blood examination. These authors also
reported a patient with the same infectious condition in
268 children with high epidemiologic risk for Chagas dis-
ease (6). In Brazil, Avila et al. (7) observed three discor-
dant cases, one of which had typical findings of myocar-
dial damage. Similarly, Castro et al. (9) detected 3 persons
with positive PCR results among 9 seronegative controls,
and Gomez et al. (8), reported 10 positive PCR results in
seronegative patients of 110 residents of a highly disease-
endemic region. 
Several arguments have been proposed to explain this
controversial situation. Recent infection that has not yet
been recognized by the immune system of persons highly
exposed to vectorial infections is one possible explanation.
However, acute infection is not a frequent event in our
study population because of age and because urban popu-
lation is infrequently exposed to vectorial reinfection.
Alternatively, one could speculate that positive samples
could have been contaminated with DNA, but this theory
has been disregarded by many authors (8,9). We repeated
serologic and PCR assays three times for each patient with
two different operators, and we obtained the same results.
Finally, T. cruzi may chronically infect some patients but a
humoral response may not develop or be detected by con-
ventional serologic testing. Addressing this point, Castro et
al. (9) observed that 80% of seronegative but positive PCR
patients had lytic antibodies against T. cruzi by a comple-
ment-mediated lysis test (CoML). Similarly, Leguizamón
et al. (15) have reported patients who were seropositive for
Chagas disease only by inhibition transamidase assay but
negative with conventional serologic testing. To test this
hypothesis, we searched for anti-cruzipain antibodies in
eight rural patients, but all of them were negative.
Otherwise, independently of its cause, considering the
clinical and diagnostic consequences of this phenomenon
is necessary. In our study, at least 3 of the 12 patients with
high epidemiologic risk for Chagas disease had signs of
cardiac compromise. The consensus is that the detection of
DNA constitutes real proof of parasites. DNA detected in
blood is originated from extracellular parasites recently
liberated or destroyed. According to this theory, Tarleton
and Zhang observed that after injection of high doses of
kinetoplastic DNA(kDNA) of T. cruzi in muscle, kDNAis
detected in blood 2 days later (16). However, since the par-
asite is infective as tripomastigotes but not as a portion of
DNA, we cannot be sure that DNA detected by PCR in
blood is a reliable surrogate of infecting T. cruzi forms.
One alternative is the possibility that fragments of amasti-
gotes (the tissue-infecting forms) reach the bloodstream
after interacting with the immune system. Even though this
consideration may be found relevant in the design of trans-
fusion policies, no reliable information currently exists,
and the potential for these persons to transmit the disease
is still uncertain.
Comparing our results with a population without any
risk for Chagas disease to determine the predictive value of
PCR among seronegative persons would be interesting.
However, the accuracy of PCR has been studied in depth
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Figure. Gel electrophoresis analysis of a polymerase chain reac-
tion (PCR) product corresponding to a highly repetitive 220-bp
Trypanosoma cruzi nuclear fragment. 1: molecular weight stan-
dards, 2: T. cruzi nuclear 220-bp PCR product, 3 and 4: PCR pro-
duct from patients blood, 5: PCR negative control (arrows corres-
pond to 220 bp). (2–4,12,17). While previous reports of PCR in Chagas dis-
ease used a sequence of kDNAof T. cruzi to detect the par-
asite, we used nuclear DNA that has been also validated
(12,13). Currently, we have not carried out a systematic
comparison of the PCR sensitivity for different T. cruzi
sequences. We considered determining which of the differ-
ent PCR systems cited in the literature is the more sensi-
tive and accurate for detection of parasitemia in blood
specimens of patients with chronic Chagas disease.
In summary, we found a prevalence of 15% of T. cruzi
DNAfor American trypanosomiasis in a seronegative pop-
ulation living in Chagas-endemic regions. We also
observed that some of these persons had cardiac abnormal-
ities suggestive of Chagas cardiomyopathy. Experts should
consider these finding when making diagnostic, therapeu-
tic, and transfusion recommendations.
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Table 2. Epidemiologic and clinical characteristics of 12 patients with negative serologic findings and positive PCR for T. cruzi in blood  
Echocardiogram
 
Patient  Age (y)  Sex
 
Previous positive 
serologic test  ECG
  LVDd (mm)  LVEF (%) 
Urban 1  56  F  Present  Normal  44  64 
Urban 2  66  F  Absent  RBBB  42  65 
Urban 3  58  M  Absent  RBBB + LAFB  45  60 
Rural 1  35  F  Absent  ND  ND  ND 
Rural 2  17  F  Absent  ND  ND  ND 
Rural 3  15  F  Absent  ND  ND  ND 
Rural 4  47  F  Absent  Normal  45  50 
Rural 5  59  M  Absent  ND  ND  ND 
Rural 6  22  F  Absent  ND  ND  ND 
Rural 7  24  M  Absent  IRBBB  50  45 
Rural 8  68  M  Absent  Normal  39  56 
Rural 9  43  F  Absent  Normal  46  64 
aPCR, polymerase chain reaction; F, female; M, male; ECG, electrocardiogram; RBBB, right bundle branch block; IRBBB, incomplete right bundle branch block; LAFB, 
left anterior fascicular block; LVDd, left ventricular diameter in diastole; LVEF, left ventricular ejection fraction; ND, not determinate. 14. Tarleton RL. Parasite persistence in the aetiology of Chagas disease.
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